Potentially Transformational Regenerative Biotechnology-Derived Protein Therapy Platform
What is Regenerative Medicine?
A class of medicines that aim to grow, repair or replace damaged or diseases cells, tissues or organs. Regenerative medicine goes beyond treating diseases or managing symptoms and seeks to develop cures. However, a significant shortcoming of cell therapy is the body’s immune system working to seek out and kill foreign cells, tissues, organoids and organs implanted into the body, requiring the need for life-long immunosuppression.
iTOL-100: Our Biotechnology-Derived Protein Inducing Immune Tolerance Platform
Through a data-driven approach, we are working to enable regenerative medicine without the need for life-long immunosuppression. Our platform technology, iTOL-100, leverages the naturally occurring protein, Fas Ligand (FasL) which is present in all mammals and functions as a natural way for the body to establish local immune tolerance.
iTOL-100 is a biotechnology derived pharmaceutical product, a chimeric fusion protein of streptavidin-FasL in a synthetic biomaterial microgel synthesized through a straightforward process. Ordinarily, activated T-cells will reject foreign tissue. Current implantation of cells or organs require life-long immunosuppression to prevent organ rejection. However, when we then mix iTOL-100 with the target cell therapy and implant it into the body, the FasL binds to the Fas receptor (FasR) on activated T-cells, preventing rejection through a process called apoptosis (or programmed cell death). In parallel, T-regulatory cells are generated creating localized immune privilege and protecting the implanted cell therapy.
In preclinical studies, our iTOL-100 platform has been shown to establish durable, localized immune tolerance, allowing the implanted tissue, organoid or cell therapy to function as a replacement for damaged native cells.